Appendix 7: Forest plots [posted as supplied by author]

Figure 3: Zanamivir versus placebo for treatment. Time to first alleviation of symptoms in adult treatment [days].

| | Zar | Zanamivir Placebo | | | | | | Mean Difference | Mean Difference |
|-----------------------------------|---------|-------------------|-------|-------|------|-------|--------|----------------------|-----------------------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| JNAI-01 | 3.13 | 1.33 | 29 | 3.9 | 0.96 | 31 | 10.7% | -0.77 [-1.36, -0.18] | |
| JNAI-04 | 3.84 | 2.06 | 32 | 5.68 | 2.75 | 16 | 1.8% | -1.84 [-3.36, -0.32] | |
| JNAI-07 | 4.41 | 1.95 | 211 | 4.67 | 1.98 | 107 | 16.3% | -0.26 [-0.72, 0.20] | + |
| NAI30008 | 9.61 | 8.11 | 262 | 10.72 | 8.46 | 263 | 2.1% | -1.11 [-2.53, 0.31] | |
| NAI30010 | 7.11 | 6.52 | 163 | 7.93 | 6.58 | 158 | 2.0% | -0.82 [-2.25, 0.61] | |
| NAI30012 | 10.45 | 8.89 | 191 | 10.93 | 8.47 | 169 | 1.3% | -0.48 [-2.27, 1.31] | |
| NAI30015 | 4.29 | 5.23 | 293 | 4.86 | 5.64 | 295 | 5.2% | -0.57 [-1.45, 0.31] | + |
| NAIA/B2008 | 5.87 | 2.46 | 834 | 6.34 | 2.25 | 422 | 33.8% | -0.47 [-0.74, -0.20] | - |
| NAIA2005 | 5.29 | 2.31 | 139 | 5.7 | 2.49 | 81 | 8.7% | -0.41 [-1.07, 0.25] | + |
| NAIA3002 | 8.34 | 7.4 | 412 | 8.9 | 7.77 | 365 | 3.6% | -0.56 [-1.63, 0.51] | |
| NAIB2005 | 5.06 | 2.33 | 64 | 5.9 | 2.73 | 63 | 5.1% | -0.84 [-1.72, 0.04] | |
| NAIB3001 | 6.48 | 3.74 | 227 | 7.35 | 3.83 | 228 | 8.0% | -0.87 [-1.57, -0.17] | |
| NAIB3002 | 7.97 | 7.32 | 174 | 10.58 | 8.53 | 182 | 1.5% | -2.61 [-4.26, -0.96] | |
| Total (95% CI) | | | 3031 | | | 2380 | 100.0% | -0.60 [-0.81, -0.39] | • |
| Heterogeneity: Tau ² = | 0.01; C | | | | | | | | |
| Test for overall effect: | | -4 -2 U Z 4 | | | | | | | |
| | | , | | ′ | | | | | Favours zanamivir Favours placebo |

Figure 4: Zanamivir versus placebo for treatment. Time to first alleviation of symptoms in children (days).

| | Zai | anamivir Placebo | | | Mean Difference | | Mean Difference | | |
|--|------|---|-------|------|-----------------|-------|-----------------|----------------------|--------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| NAI30009 | 6.12 | 5.68 | 224 | 7.96 | 7.6 | 247 | 41.0% | -1.84 [-3.04, -0.64] | + |
| NAI30028 | 8.1 | 2.23 | 172 | 8.66 | 2.05 | 80 | 59.0% | -0.56 [-1.12, -0.00] | |
| Total (95% CI) | | | 396 | | | 327 | 100.0% | -1.08 [-2.32, 0.15] | • |
| Heterogeneity: Tau² = Test for overall effect | Ī | -4 -2 0 2 4 Favours zanamivir Favours placebo | | | | | | | |

Figure 5: Time to first alleviation of symptoms in adults by infection status




Figure 6: Zanamivir versus placebo for prophylaxis. Symptomatic influenza in prophylaxis of individuals.

| | Zanamivir Placebo | | | Risk Ratio | Risk Ratio | | |
|--------------------------|-------------------|----------|-------------------|------------|------------|--------------------|-----------------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| 167-101 | 3 | 160 | 6 | 156 | 13.7% | 0.49 [0.12, 1.92] | |
| NAI30034 | 4 | 1678 | 23 | 1685 | 19.7% | 0.17 [0.06, 0.50] | |
| NAIA3004 | 15 | 240 | 23 | 249 | 34.3% | 0.68 [0.36, 1.27] | - ■+ |
| NAIA3005 | 11 | 553 | 34 | 554 | 32.4% | 0.32 [0.17, 0.63] | - |
| Total (95% CI) | | 2631 | | 2644 | 100.0% | 0.39 [0.22, 0.70] | • |
| Total events | 33 | | 86 | | | | |
| Heterogeneity: Tau² = | 0.15; Ch | % | 0.01 0.1 1 10 100 | | | | |
| Test for overall effect: | Z= 3.17 (| (P = 0.0 | 102) | | | | Favours zanamivir Favours placebo |

Figure 7: Zanamivir versus placebo for prophylaxis. Symptomatic influenza in post-exposure prophylaxis of households.

| | Zanam | ivir | Place | bo | | Risk Ratio | Risk Ratio | | |
|---|------------|-------------------|-------------|---------|-----------------|--------------------|--------------------|--|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI | | |
| 4.3.1 Household prop | hylaxis | | | | | | | | |
| NAI30010 | 7 | 169 | 32 | 168 | 26.6% | 0.22 [0.10, 0.48] | | | |
| NAI30031 | 10 | 245 | 46 | 242 | 31.3% | 0.21 [0.11, 0.42] | - | | |
| Subtotal (95% CI) | | 414 | | 410 | 57.8% | 0.22 [0.13, 0.36] | • | | |
| Total events | 17 | | 78 | | | | | | |
| Heterogeneity: Tau ² = 0.00; Chi ² = 0.00, df = 1 (P = 0.98); I^2 = 0% | | | | | | | | | |
| Test for overall effect: | Z = 5.93 (| (P < 0.0 | 10001) | | | | | | |
| 4.3.2 Other prophylax | xis | | | | | | | | |
| NAIA/B2009 | 16 | 431 | 9 | 144 | 26.4% | 0.59 [0.27, 1.31] | | | |
| NAIA2006 | 0 | 49 | 1 | 15 | 3.1% | 0.11 [0.00, 2.49] | | | |
| NAIB2006 | 3 | 30 | 4 | 32 | 12.7% | 0.80 [0.19, 3.28] | | | |
| Subtotal (95% CI) | | 510 | | 191 | 42.2% | 0.59 [0.30, 1.16] | • | | |
| Total events | 19 | | 14 | | | | | | |
| Heterogeneity: Tau ² = | 0.00; Chi | $i^2 = 1.3^\circ$ | 1, df = 2 (| P = 0.5 | 2); $I^2 = 0.9$ | 6 | | | |
| Test for overall effect: | Z = 1.54 (| P = 0.1 | 2) | | | | | | |
| Total (95% CI) | | 924 | | 601 | 100.0% | 0.33 [0.18, 0.58] | • | | |
| Total events | 36 | | 92 | | | | | | |
| Heterogeneity: Tau ² = 0.16; Chi ² = 6.71, df = 4 (P = 0.15); I ² = 40% | | | | | | | | | |
| Test for overall effect: | Z = 3.82 (| | | | | | | | |
| Test for subgroup differences: $Chi^2 = 5.40$, $df = 1$ (P = 0.02), $I^2 = 81.5\%$ Favours zanamivir Favours placebo | | | | | | | | | |

Figure 8: Zanamivir versus placebo for prophylaxis. Asymptomatic influenza in post-exposure prophylaxis of individuals.

| | Zanami | VİF | Placebo | | Risk Ratio | | Risk Ratio |
|--------------------------|------------------------|--------|--|-------|------------|--------------------|--------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | IV, Random, 95% Cl | IV, Random, 95% CI |
| 167-101 | 5 | 160 | 10 | 156 | 5.4% | 0.49 [0.17, 1.39] | |
| NAI30034 | 35 | 1678 | 31 | 1685 | 26.2% | 1.13 [0.70, 1.83] | + |
| NAIA3004 | 34 | 240 | 37 | 249 | 32.4% | 0.95 [0.62, 1.47] | + |
| NAIA3005 | 42 | 553 | 43 | 554 | 36.0% | 0.98 [0.65, 1.47] | + |
| Total (95% CI) | | 2631 | | 2644 | 100.0% | 0.97 [0.76, 1.24] | • |
| Total events | 116 | | 121 | | | | |
| Heterogeneity: Tau²= | 0.00; Chi ^a | (0 | 0.01 0.1 1 10 100 | | | | |
| Test for overall effect: | Z = 0.24 (F | | 0.01 0.1 1 10 100 Favours zanamivir Favours placebo | | | | |

Figure 9: Zanamivir versus placebo for prophylaxis. Asymptomatic influenza in post-exposure prophylaxis of households.

| | Zanamiv | Zanamivir Placebo | | Risk Ratio | | Risk Ratio | |
|--------------------------|--------------------------|-------------------|-------------------|------------|--------|--------------------|-----------------------------------|
| Study or Subgroup | Events Total | | Events | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| NAI30010 | 15 | 169 | 15 | 168 | 20.5% | 0.99 [0.50, 1.97] | - |
| NAI30031 | 25 | 245 | 29 | 242 | 37.6% | 0.85 [0.51, 1.41] | - |
| NAIA/B2009 | 49 | 431 | 18 | 144 | 37.4% | 0.91 [0.55, 1.51] | - |
| NAIA2006 | 1 | 49 | 1 | 15 | 1.3% | 0.31 [0.02, 4.60] | |
| NAIB2006 | 2 | 30 | 3 | 32 | 3.2% | 0.71 [0.13, 3.97] | |
| Total (95% CI) | | 924 | | 601 | 100.0% | 0.88 [0.65, 1.20] | • |
| Total events | 92 | | 66 | | | | |
| Heterogeneity: Tau² = | 0.00°_{1} Chi²: | 6 | 0.01 0.1 1 10 100 | | | | |
| Test for overall effect: | Z= 0.78 (P |) = 0.4 | 3) | | | | Favours zanamivir Favours placebo |

Figure 10: Zanamivir versus placebo for treatment. Complications: pneumonia confirmed with X-ray in adult treatment.

| | Zanamivir Placel | | bo Risk Ratio | | | Risk Ratio | |
|-----------------------------------|------------------|----------|--------------------|-------|--------|--------------------|-----------------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | IV, Random, 95% Cl | IV, Random, 95% CI |
| NAI30012 | 2 | 191 | 4 | 167 | 29.7% | 0.44 [0.08, 2.36] | - |
| NAI30015 | 16 | 293 | 11 | 295 | 70.3% | 1.46 [0.69, 3.10] | • |
| Total (95% CI) | | 484 | | 462 | 100.0% | 1.02 [0.35, 3.02] | • |
| Total events | 18 | | 15 | | | | |
| Heterogeneity: Tau ² = | 0.29; Ch | % | 0.002 0.1 1 10 500 | | | | |
| Test for overall effect: | Z= 0.04 | (P = 0.9 | 37) | | | | Favours zanamivir Favours placebo |

Figure 11: Complications: Mixed verified and unverified pneumonia in adult treatment.

| | Zanam | ivir | Place | bo | | Risk Ratio | Risk Ratio |
|--------------------------|------------|--|-----------------|-------|--------|--------------------|---|
| Study or Subgroup | Events | Total | Events | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| NAI30008 | 1 | 262 | 2 | 263 | 3.3% | 0.50 [0.05, 5.50] | - |
| NAI30010 | 1 | 163 | 0 | 158 | 1.9% | 2.91 [0.12, 70.87] | |
| NAI30011 | 2 | 229 | 3 | 237 | 6.0% | 0.69 [0.12, 4.09] | |
| NAI30012 | 6 | 191 | 6 | 167 | 15.4% | 0.87 [0.29, 2.66] | |
| NAI30015 | 16 | 293 | 12 | 295 | 35.8% | 1.34 [0.65, 2.79] | - |
| NAIA/B2008 | 8 | 834 | 2 | 422 | 8.0% | 2.02 [0.43, 9.49] | • |
| NAIA2005 | 2 | 139 | 0 | 81 | 2.1% | 2.93 [0.14, 60.26] | - - |
| NAIA3002 | 5 | 412 | 6 | 365 | 13.8% | 0.74 [0.23, 2.40] | |
| NAIB2007 | 0 | 371 | 2 | 183 | 2.1% | 0.10 [0.00, 2.05] | |
| NAIB3001 | 2 | 227 | 5 | 228 | 7.2% | 0.40 [0.08, 2.05] | |
| NAIB3002 | 1 | 174 | 7 | 182 | 4.4% | 0.15 [0.02, 1.20] | - |
| Total (95% CI) | | 3295 | | 2581 | 100.0% | 0.90 [0.58, 1.40] | • |
| Total events | 44 | | 45 | | | | |
| Heterogeneity: Tau² = | 0.00; Chi | % | 004 04 4 40 400 | | | | |
| Test for overall effect: | Z = 0.45 (| 0.01 0.1 1 10 100 Favours zanamivir Favours placebo | | | | | |

Figure 12: Complications: self reported investigator mediated unverified pneumonia in adult prophylaxis.

| | Zanamivir | | Place | bo | | Risk Ratio | Risk | Ratio |
|--------------------------|------------|-------|-------------------|---------|--------|--------------------|-----------|-----------|
| Study or Subgroup | Events | Total | Events | Total | Weight | IV, Random, 95% CI | IV, Rando | m, 95% CI |
| NAI30010 | 0 | 407 | 3 | 430 | 11.3% | 0.15 [0.01, 2.91] | | _ |
| NAI30031 | 1 | 661 | 3 | 630 | 19.3% | 0.32 [0.03, 3.05] | | <u> </u> |
| NAI30034 | 2 | 1678 | 6 | 1685 | 38.6% | 0.33 [0.07, 1.66] | - | _ |
| NAIA/B2009 | 1 | 431 | 0 | 144 | 9.7% | 1.01 [0.04, 24.58] | | |
| NAIA3004 | 0 | 240 | 4 | 249 | 11.6% | 0.12 [0.01, 2.13] | | <u> </u> |
| NAIA3005 | 0 | 553 | 1 | 554 | 9.6% | 0.33 [0.01, 8.18] | | |
| Total (95% CI) | | 3970 | | 3692 | 100.0% | 0.30 [0.11, 0.80] | • | |
| Total events | 4 | | 17 | | | | | |
| Heterogeneity: Tau² = | : 0.00; Ch | 6 | 0.001 0.1 | 10 1000 | | | | |
| Test for overall effect: | Z= 2.39 i | | Favours zanamivir | | | | | |

Figure 13: Complications: bronchitis in adult treatment.

| | Zanam | ivir | Place | bo | | Risk Ratio | | Risk Ratio |) | |
|--------------------------|------------|--------------|----------------------|-----------------|--------|--------------------|-----|----------------|-------|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | IV, Random, 95% CI | IV, | Random, 9 | 5% CI | |
| NAI30008 | 40 | 262 | 45 | 263 | 26.3% | 0.89 [0.60, 1.32] | | + | | |
| NAI30010 | 1 | 163 | 3 | 158 | 0.8% | 0.32 [0.03, 3.07] | _ | | | |
| NAI30011 | 8 | 229 | 5 | 237 | 3.3% | 1.66 [0.55, 4.99] | | +- | | |
| NAI30012 | 18 | 191 | 27 | 167 | 12.8% | 0.58 [0.33, 1.02] | | - | | |
| NAI30015 | 11 | 293 | 16 | 295 | 7.1% | 0.69 [0.33, 1.47] | | - | | |
| NAIA/B2008 | 33 | 834 | 24 | 422 | 15.2% | 0.70 [0.42, 1.16] | | | | |
| NAIA2005 | 2 | 139 | 3 | 81 | 1.3% | 0.39 [0.07, 2.28] | | | | |
| NAIA3002 | 19 | 412 | 20 | 365 | 10.7% | 0.84 [0.46, 1.55] | | + | | |
| NAIB2005 | 0 | 134 | 1 | 62 | 0.4% | 0.16 [0.01, 3.77] | | - | | |
| NAIB2007 | 18 | 371 | 14 | 183 | 8.8% | 0.63 [0.32, 1.25] | | -+ | | |
| NAIB3001 | 9 | 227 | 22 | 228 | 7.1% | 0.41 [0.19, 0.87] | | | | |
| NAIB3002 | 13 | 174 | 10 | 182 | 6.3% | 1.36 [0.61, 3.02] | | + | | |
| Total (95% CI) | | 3429 | | 2643 | 100.0% | 0.75 [0.61, 0.91] | | • | | |
| Total events | 172 | | 190 | | | | | | | |
| Heterogeneity: Tau² = | 0.00; Chi | 0.004 | + + | 10 | 1000 | | | | | |
| Test for overall effect: | Z = 2.88 (| | D.1 1 namivir Fav | 10 ours plac | 1000 | | | | | |
| | , | r avours Zai | iaiilivii Fav | ours pla | CEDO | | | | | |

Figure 14: Complications: otitis media in adult treatment.

| | Zanamivir | | Placebo | | | Risk Ratio | Risk Ratio |
|-----------------------------------|-------------|-------|---|-------|--------|--------------------|--------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| NAI30008 | 3 | 262 | 7 | 263 | 8.8% | 0.43 [0.11, 1.65] | |
| NAI30010 | 4 | 163 | 6 | 158 | 10.2% | 0.65 [0.19, 2.25] | |
| NAI30011 | 0 | 229 | 1 | 237 | 1.6% | 0.34 [0.01, 8.42] | |
| NAI30015 | 11 | 293 | 7 | 295 | 18.2% | 1.58 [0.62, 4.03] | +- |
| NAIA/B2008 | 7 | 834 | 6 | 422 | 13.5% | 0.59 [0.20, 1.75] | |
| NAIA3002 | 9 | 412 | 9 | 365 | 19.0% | 0.89 [0.36, 2.21] | - |
| NAIB2005 | 1 | 134 | 1 | 62 | 2.1% | 0.46 [0.03, 7.28] | |
| NAIB2007 | 5 | 371 | 3 | 183 | 7.9% | 0.82 [0.20, 3.40] | |
| NAIB3001 | 7 | 227 | 8 | 228 | 15.9% | 0.88 [0.32, 2.38] | - |
| NAIB3002 | 1 | 174 | 2 | 182 | 2.8% | 0.52 [0.05, 5.72] | |
| Total (95% CI) | | 3099 | | 2395 | 100.0% | 0.81 [0.54, 1.20] | • |
| Total events | 48 | | 50 | | | | |
| Heterogeneity: Tau ² = | : 0.00; Chi | 6 | | | | | |
| Test for overall effect: | Z = 1.06 (| | 0.01 0.1 1 10 100 Favours zanamivir Favours placebo | | | | |

Figure 15: Complications: sinusitis in adult treatment.

| | | Zanamivir Pla | | | | Risk Ratio | Risk Ratio |
|-----------------------------------|-----------|-------------------|--------|-------|--------|--------------------|-----------------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| NAI30008 | 30 | 262 | 17 | 263 | 14.1% | 1.77 [1.00, 3.13] | - |
| NAI30010 | 7 | 163 | 3 | 158 | 3.9% | 2.26 [0.60, 8.59] | +• |
| NAI30011 | 2 | 229 | 8 | 237 | 3.0% | 0.26 [0.06, 1.21] | |
| NAI30012 | 7 | 191 | 4 | 167 | 4.6% | 1.53 [0.46, 5.14] | |
| NAI30015 | 83 | 293 | 90 | 295 | 26.4% | 0.93 [0.72, 1.19] | + |
| NAIA/B2008 | 23 | 834 | 12 | 422 | 11.1% | 0.97 [0.49, 1.93] | + |
| NAIA2005 | 8 | 139 | 2 | 81 | 3.1% | 2.33 [0.51, 10.71] | + |
| NAIA3002 | 24 | 412 | 22 | 365 | 14.3% | 0.97 [0.55, 1.69] | + |
| NAIB2005 | 6 | 134 | 1 | 62 | 1.7% | 2.78 [0.34, 22.57] | |
| NAIB2007 | 8 | 371 | 5 | 183 | 5.4% | 0.79 [0.26, 2.38] | |
| NAIB3001 | 10 | 227 | 3 | 228 | 4.2% | 3.35 [0.93, 12.01] | - |
| NAIB3002 | 8 | 174 | 13 | 182 | 8.1% | 0.64 [0.27, 1.51] | |
| Total (95% CI) | | 3429 | | 2643 | 100.0% | 1.12 [0.84, 1.48] | • |
| Total events | 216 | | 180 | | | | |
| Heterogeneity: Tau ² = | 0.06; Chi | 1004 | | | | | |
| Test for overall effect: | - | 0.01 0.1 1 10 100 | | | | | |
| | | | | | | | Favours zanamivir Favours placebo |

Figure 16: Complications classified as serious or leading to study withdrawal in adult treatment.

| | Zanamivir | | Placebo | | Risk Ratio | | Risk Ratio | |
|---|-----------|-------|---------------|-------|------------|--------------------|---|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI | |
| NAI30008 | 0 | 262 | 3 | 263 | 8.7% | 0.14 [0.01, 2.76] | | |
| NAI30010 | 1 | 163 | 0 | 158 | 7.5% | 2.91 [0.12, 70.87] | | |
| NAI30011 | 1 | 229 | 0 | 237 | 7.5% | 3.10 [0.13, 75.81] | - | |
| NAI30012 | 3 | 191 | 3 | 167 | 30.4% | 0.87 [0.18, 4.27] | | |
| NAIA/B2008 | 2 | 834 | 0 | 422 | 8.3% | 2.53 [0.12, 52.64] | | |
| NAIA3002 | 2 | 412 | 2 | 365 | 20.0% | 0.89 [0.13, 6.26] | | |
| NAIB3001 | 1 | 227 | 1 | 228 | 10.0% | 1.00 [0.06, 15.96] | | |
| NAIB3002 | 1 | 174 | 0 | 182 | 7.5% | 3.14 [0.13, 76.49] | - | |
| Total (95% CI) | | 2492 | | 2022 | 100.0% | 1.10 [0.46, 2.63] | • | |
| Total events | 11 | | 9 | | | | | |
| Heterogeneity: Tau² = 0.00; Chi² = 3.42, df = 7 (P = 0.84); l² = 0% | | | | | | | 0.04 0.4 4 40 400 | |
| Test for overall effect: $Z = 0.21$ (P = 0.83) | | | | | | | 0.01 0.1 1 10 100 Favours zanamivir Favours placebo | |

Figure 17: Complications classified as serious or leading to study withdrawal in adult prophylaxis.

| | Zanam | ivir | Place | bo | | Risk Ratio | Risk Ratio | |
|---|--------|-------|--------|-------|--------|---------------------|-------------------------------|----------|
| Study or Subgroup | Events | Total | Events | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI | |
| NAI30031 | 1 | 661 | 1 | 630 | 15.8% | 0.95 [0.06, 15.21] | | |
| NAI30034 | 3 | 1678 | 3 | 1685 | 47.4% | 1.00 [0.20, 4.97] | - | |
| NAIA/B2009 | 1 | 431 | 0 | 144 | 11.9% | 1.01 [0.04, 24.58] | | _ |
| NAIA3004 | 2 | 240 | 0 | 249 | 13.2% | 5.19 [0.25, 107.48] | - | → |
| NAIA3005 | 0 | 553 | 1 | 554 | 11.8% | 0.33 [0.01, 8.18] | - | |
| Total (95% CI) | | 3563 | | 3262 | 100.0% | 1.09 [0.36, 3.26] | • | |
| Total events | 7 | | 5 | | | | | |
| Heterogeneity: Tau ² = 0.00; Chi ² = 1.56, df = 4 (P = 0.82); I^2 = 0% $I = 0.01$ 0.1 1 10 11 | | | | | | | | |
| Test for overall effect: $Z = 0.15$ (P = 0.88) | | | | | | | Favours zanamivir Favours pla | |

Figure 18: Adverse events: nausea and vomiting in adult treatment (on-treatment)

| | Zanamivir | | Placebo | | Risk Ratio | | Risk Ratio | |
|--|-----------|-------------------|---------------|-------|------------|----------------------|---|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI | |
| JNAI-01 | 4 | 77 | 5 | 39 | 6.8% | 0.41 [0.12, 1.42] | | |
| JNAI-04 | 0 | 32 | 1 | 16 | 1.7% | 0.17 [0.01, 3.99] | | |
| JNAI-07 | 5 | 214 | 9 | 110 | 8.0% | 0.29 [0.10, 0.83] | | |
| NAI30008 | 5 | 261 | 19 | 263 | 8.8% | 0.27 [0.10, 0.70] | | |
| NAI30010 | 2 | 161 | 8 | 160 | 5.3% | 0.25 [0.05, 1.15] | | |
| NAI30011 | 5 | 229 | 6 | 237 | 7.3% | 0.86 [0.27, 2.79] | | |
| NAI30012 | 9 | 191 | 0 | 166 | 2.1% | 16.53 [0.97, 281.80] | <u> </u> | |
| NAI30015 | 0 | 293 | 2 | 295 | 1.8% | 0.20 [0.01, 4.18] | | |
| NAIA/B2008 | 20 | 834 | 14 | 422 | 11.3% | 0.72 [0.37, 1.42] | | |
| NAIA2005 | 30 | 139 | 11 | 81 | 11.7% | 1.59 [0.84, 3.00] | • | |
| NAIA3002 | 12 | 412 | 19 | 365 | 11.0% | 0.56 [0.28, 1.14] | | |
| NAIB2005 | 2 | 134 | 5 | 62 | 5.0% | 0.19 [0.04, 0.93] | | |
| NAIB2007 | 11 | 369 | 2 | 180 | 5.5% | 2.68 [0.60, 11.98] | • | |
| NAIB3001 | 4 | 227 | 8 | 228 | 7.2% | 0.50 [0.15, 1.64] | | |
| NAIB3002 | 4 | 174 | 5 | 182 | 6.5% | 0.84 [0.23, 3.07] | _ | |
| Total (95% CI) | | 3747 | | 2806 | 100.0% | 0.60 [0.39, 0.94] | • | |
| Total events | 113 | | 114 | | | | | |
| Heterogeneity: Tau² = | 0.32; Chi | 0.01 0.1 1 10 100 | | | | | | |
| Test for overall effect: $Z = 2.25$ (P = 0.02) | | | | | | | Favours zanamivir Favours placebo | |
| | | | | | | | i avours zariarilivii - Favours placebo | |